loader
Please Wait
Applying Filters...

Technical details about Bufalin, learn more about the structure, uses, toxicity, action, side effects and more

Client Email Product
Menu
Xls
2D Structure
Also known as: 465-21-4, 3-beta,14-dihydroxy-5-beta-bufa-20,22-dienolide, 3,14-dihydroxy-bufa-20,22-dienolide, U549s98qlw, 5-((3s,5r,8r,9s,10s,13r,14s,17r)-3,14-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2h-pyran-2-one, Chebi:517248
Molecular Formula
C24H34O4
Molecular Weight
386.5  g/mol
InChI Key
QEEBRPGZBVVINN-BMPKRDENSA-N
FDA UNII
U549S98QLW

Bufalin is an active ingredient and one of the glycosides in the traditional Chinese medicine ChanSu; it is also a bufadienolide toxin originally isolated from the venom of the Chinese toad Bufo gargarizans, with potential cardiotonic and antineoplastic activity. Although the mechanism of action of bufalin is still under investigation, this agent is a specific Na+/K+-ATPase inhibitor and can induce apoptosis in cancer cell lines through the activation of the transcription factor AP-1 via a mitogen activated protein kinase (MAPK) pathway.
1 2D Structure

2D Structure

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one
2.1.2 InChI
InChI=1S/C24H34O4/c1-22-10-7-17(25)13-16(22)4-5-20-19(22)8-11-23(2)18(9-12-24(20,23)27)15-3-6-21(26)28-14-15/h3,6,14,16-20,25,27H,4-5,7-13H2,1-2H3/t16-,17+,18-,19+,20-,22+,23-,24+/m1/s1
2.1.3 InChI Key
QEEBRPGZBVVINN-BMPKRDENSA-N
2.1.4 Canonical SMILES
CC12CCC(CC1CCC3C2CCC4(C3(CCC4C5=COC(=O)C=C5)O)C)O
2.1.5 Isomeric SMILES
C[C@]12CC[C@@H](C[C@H]1CC[C@@H]3[C@@H]2CC[C@]4([C@@]3(CC[C@@H]4C5=COC(=O)C=C5)O)C)O
2.2 Other Identifiers
2.2.1 UNII
U549S98QLW
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Bufalin, (3alpha,5beta)-isomer

2.3.2 Depositor-Supplied Synonyms

1. 465-21-4

2. 3-beta,14-dihydroxy-5-beta-bufa-20,22-dienolide

3. 3,14-dihydroxy-bufa-20,22-dienolide

4. U549s98qlw

5. 5-((3s,5r,8r,9s,10s,13r,14s,17r)-3,14-dihydroxy-10,13-dimethylhexadecahydro-1h-cyclopenta[a]phenanthren-17-yl)-2h-pyran-2-one

6. Chebi:517248

7. 3beta,14beta-dihydroxy-5beta-bufa-20,22-dienolide

8. 5-[(3s,5r,8r,9s,10s,13r,14s,17r)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one

9. Unii-u549s98qlw

10. Nsc-89595

11. Ch'an Su

12. Buf

13. Nsc 89595

14. Brn 5141601

15. Bufalin [mi]

16. (3beta,5beta)-3,14-dihydroxybufa-20,22-dienolide

17. Bufalin [who-dd]

18. Schembl165666

19. Bufa-20,22-dienolide, 3,14-dihydroxy-, (3.beta.,5.beta.)-

20. Chembl399680

21. Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-

22. Dtxsid90873563

23. Amy40632

24. Bufalin: Bufa-20,22-dienolide, 3,14-dihydroxy-, (3b,5b)-,

25. Hy-n0877

26. Zinc4215121

27. Hsci1_000110

28. Lmst01130001

29. Mfcd30207876

30. S7821

31. Akos015965454

32. Cs-3694

33. Smp2_000290

34. Ac-20197

35. Ac-34068

36. Bs-17080

37. C16922

38. 5beta-bufa-20,22-dienolide, 3beta,14-dihydroxy-

39. Brd-k63606607-001-01-8

40. Brd-k63606607-001-02-6

41. Q18379323

42. 5-beta-bufa-20,22-dienolide, 3-beta,14-dihydroxy-

43. Bufa-20,22-dienolide, 3,14-dihydroxy-, (3beta,5beta)-

44. Bufa-20,22-dienolide, 3,14-dihydroxy-, (3-beta,5-beta)-

45. (3beta,5beta,10alpha,17alpha)-3,14-dihydroxybufa-20,22-dienolide

2.4 Create Date
2006-08-30
3 Chemical and Physical Properties
Molecular Weight 386.5 g/mol
Molecular Formula C24H34O4
XLogP33.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count4
Rotatable Bond Count1
Exact Mass386.24570956 g/mol
Monoisotopic Mass386.24570956 g/mol
Topological Polar Surface Area66.8 Ų
Heavy Atom Count28
Formal Charge0
Complexity741
Isotope Atom Count0
Defined Atom Stereocenter Count8
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Cardiotonic Agents

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE). (See all compounds classified as Cardiotonic Agents.)


Enzyme Inhibitors

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)